Pharmaceuticals

ER-KANG

ER-KANG released FY2026 Q1 earnings on April 23 After-Market (BJT), actual revenue CNY 247.39 M, actual EPS CNY 0.0064

ER-KANG released FY2025 Annual Earnings on April 22 After-Market (BJT), actual revenue CNY 1.166 B, actual EPS CNY -0.1841

ER-KANG released FY2025 Q4 earnings on April 22 After-Market (BJT), actual revenue CNY 159.34 M, actual EPS CNY -0.2027

ER-KANG to Release FY2026 Q1 Earnings on April 24 After-Market (BJT)

ER-KANG to Release FY2025 Earnings on April 23 After-Market (BJT)

ER-KANG released FY2025 9 Months Earnings on October 29 During-Market BJT, actual revenue CNY 1.006 B, actual EPS CNY 0.0191

ER-KANG released FY2025 Q3 earnings on October 29 During-Market (BJT), actual revenue CNY 324.54 M, actual EPS CNY 0.0009

ER-KANG FY2025 Q3 Earning Release on October 30, 2025 During-Market (BJT)

ER-KANG released FY2025 Q2 earnings on August 27 After-Market (BJT), actual revenue CNY 328.33 M, actual EPS CNY 0.0046

ER-KANG released FY2025 Semi-Annual earnings on August 27 After-Market (BJT), actual revenue CNY 681.88 M, actual EPS CNY 0.0182

ER-KANG to Release FY2025 Semi-Annual Earnings on August 28, 2025 (BJT)

Er Kang Pharmaceutical's Subsidiary Plans to Invest in an Integrated Formulation Production Project in Tanzania

Er Kang Pharmaceutical's Vitamin B6 Injection Passes Consistency Evaluation and Receives Approval from NMPA

Implementation of Pharmaceutical Excipient Management Standards and Company Strategy Discussed

Er Kang Pharmaceutical Reports 868.91% Q1 2025 Net Profit Growth

Erkon Pharmaceutical Reports Widened Net Loss in 2024

ER-KANG released FY2025 Q1 earnings on April 22 After-Market (BJT), actual revenue CNY 353.55 M, actual EPS CNY 0.0136

ER-KANG released FY2024 earnings on April 22 After-Market (BJT), actual revenue CNY 1.14 B, actual EPS CNY -0.181

ER-KANG released FY2024 Q4 earnings on April 22 After-Market (BJT), actual revenue CNY 285.32 M, actual EPS CNY -0.1705

ER-KANG FY2025 Q1 Earnings Release Scheduled for April 23 After-Market BJT

300267

ER-KANG announced that its revenue for the third quarter was 325 million yuan, a year-on-year increase of 39.32%; net profit was 1.9412 million yuan, a year-on-year increase of 106.11%. Revenue for the first three quarters was 1.006 billion yuan, a year-on-year increase of 17.81%; net profit was 39.5759 million yuan, a year-on-year increase of 255.40%

Zhitong

ER-KANG: The net profit for the third quarter was 1.9412 million yuan, a year-on-year increase of 106.11%

According to the Zhitong Finance APP, ER-KANG announced that the company's controlling shareholder, Shuai Fangwen, plans to reduce his holdings of the company's shares by no more than 42 million shares, or no more than 2.04% of the company's total share capital, through centralized bidding or block trading within three months after the announcement date (from October 29, 2025, to January 28, 2026)

ER-KANG: The controlling shareholder plans to reduce its holdings by no more than 2.04%

ER-KANG released its semi-annual report for 2025, with operating revenue of 682 million yuan, a year-on-year increase of 9.74%. The net profit attributable to shareholders of the listed company was 37.6346 million yuan, a year-on-year increase of 497.36%. The net profit after deducting non-recurring gains and losses was 33.0187 million yuan, a year-on-year increase of 1357.97%. The basic earnings per share were 0.0182 yuan

ER-KANG released its performance for the first half of the year, with a net profit attributable to the parent company of 37.6346 million yuan, an increase of 497.36%

ER-KANG recently obtained the "Drug Registration Certificate" issued by the National Medical Products Administration, and its dihydroxypropyl theophylline injection has been approved for registration. This medication is a smooth muscle relaxant that has the effect of dilating the bronchi and coronary arteries, suitable for conditions such as bronchial asthma and wheezing bronchitis, especially for patients with tachycardia

ER-KANG: Dihydroxypropyl Theophylline Injection approved for registration

The board of directors of ER-KANG approved its holding subsidiary, ER-KANG Tanzania Co., Ltd., to invest USD 10 million in the construction of a comprehensive formulation production project, with a construction period of 12 months. The project aims to expand overseas investment layout, meet the needs of overseas customers, and enhance the company's economic benefits and overall competitiveness

ER-KANG's subsidiary plans to invest USD 10 million in a comprehensive formulation production project

According to the Zhitong Finance APP, ER-KANG announced that the company recently received the "Notice of Approval for Supplementary Drug Application" (Notice No.: 2025B02458) issued by the National Medical Products Administration. The company's Vitamin B6 injection 1ml:100mg specification has passed the consistency evaluation of quality and efficacy for generic drugs

ER-KANG: Vitamin B6 injection has passed the consistency evaluation of generic drugs

According to the Qichacha APP, recently, Hangzhou Langde Intelligent Technology Co., Ltd. was established, with Zhou Zhaoyi as the legal representative and a registered capital of 10 million yuan. The business scope includes: manufacturing of intelligent unmanned aerial vehicles; sales of intelligent unmanned aerial vehicles; development of artificial intelligence application software; sales of artificial intelligence hardware; research and development of intelligent robots, etc. Qichacha's equity penetration shows that the company is jointly held by Hunan Guanhe Technology Co., Ltd. and Changsha Yuean Technology Co., Ltd., both under ER-KANG

ER-KANG Pharmaceuticals and others established a smart technology company in Hangzhou

000001

399001

399006

002562

The A-share market fluctuated throughout the day, with the three major indices showing mixed results. The Shanghai Composite Index rose slightly by 0.03%, the Shenzhen Component Index fell by 0.58%, and the ChiNext Index decreased by 0.68%. Pet consumption and power stocks performed strongly, with related stocks hitting the daily limit. The vitamin concept was active, with ER-KANG and BROTHER reaching the daily limit. The cross-border payment concept declined, with Lakala falling over 10%

Wallstreetcn

SSE Index

Shenzhen Index

ChiNext

BROTHER

YIYI

CHINA PET FOODS

Lakala

DHEP

XCEP

The Shanghai Composite Index rose slightly after a peak, with pet consumption and power stocks collectively strengthening

603669

000953

The chemical pharmaceutical sector has shown strong fluctuations, with HC CHEMICAL and Lionco hitting the daily limit, ER-KANG rising over 10%, and Luoxin Pharmaceutical and Yifang Biotechnology both surging

Lionco

HC CHEMICAL

Luoxin Pharmaceutical

InventisBio

The chemical pharmaceutical sector fluctuated and strengthened, with HC CHEMICAL and Lionco hitting the limit-up

According to the Zhitong Finance APP, ER-KANG released its 2024 annual report, stating that the company's operating revenue was 1.14 billion yuan, a decrease of 36.09% year-on-year. The net loss attributable to shareholders of the listed company was 373 million yuan, an increase of 91.16% year-on-year. The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 369 million yuan, an increase of 59.24% year-on-year. The basic loss per share was 0.181 yuan

ER-KANG released its 2024 annual performance, with a net loss attributable to the parent company of 373 million yuan, an increase of 91.16%

ER-KANG(300267.SZ)